



## Final Appraisal Recommendation

Advice No: 3712 – November 2012

**Fidaxomicin (Dificlir®) 200 mg film-coated tablets**

**Submission by Astellas Pharma Ltd**

### Recommendation of the All Wales Medicines Strategy Group

**Fidaxomicin (Dificlir®) is recommended as an option for restricted use within NHS Wales.**

**Fidaxomicin (Dificlir®) should be restricted for use in the following subpopulations within its licensed indication for the treatment of adults with *Clostridium difficile* infections (CDI), also known as *C. difficile*-associated diarrhoea (CDAD):**

- Patients with severe CDI
- Patients with recurrence of CDI

**Fidaxomicin (Dificlir®) should be prescribed on the advice of a consultant microbiologist, consistent with UK Health Security Agency guidance.**

**Fidaxomicin (Dificlir®) is not recommended for use within NHS Wales outside the specified subpopulations.**

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation 3712: Fidaxomicin (Dificlir®) 200 mg tablets. November 2012.